Association of polymorphisms in the Paraoxonase 1 gene with breast cancer incidence in the CPS-II nutrition cohort

Cancer Epidemiology Biomarkers and Prevention

Volumn 15, Issue 6, 2006, Pages 1226-1228

  Stevens, Victoria L ^a   Rodriguez, Carmen ^a   Pavluck, Alexandre L ^a   Thun, Michael J ^a   Calle, Eugenia E ^a  

^a AMERICAN CANCER SOCIETY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; ARYLDIALKYLPHOSPHATASE 1; GLUTAMINE; LEUCINE; METHIONINE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DRUG USE; ENZYME ACTIVITY; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; NUTRITIONAL ASSESSMENT; POSTMENOPAUSE; PRIORITY JOURNAL; RACE DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARYLDIALKYLPHOSPHATASE; BREAST NEOPLASMS; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INCIDENCE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; POSTMENOPAUSE; RISK FACTORS;

EID: 33745683822     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-05-0930     Document Type: Article

References (22)

1. Mackness B, Durrington PN, Mackness MI. Human serum paraoxonase. Gen Pharmacol 1998;31:329-36.
2. Gan KN, Smolen A, Eskerson HW, La Du BN. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos 1991;19:100-6.
3. Mackness MI, Mackness B, Durrington PN, et al. Paraoxonase and coronary heart disease. Curr Opin Lipidol 1998;9:319-24.
4. Wheeler JG, Keavney BD, Watkins H, Collins R, Danesh J. Four paraoxonase gene polymorphisms in 11,212 case of coronary heart disease and 12,786 controls: meta-analysis of 43 studies. Lancet 2004;363:689-95.
5. Akcay MN, Yilmaz I, Polat MF, Akcay G. Serum paraoxonase levels in gastric cancer. Hepatogastroenterology 2003;50:cclxxiii-v.
6. Akcay MN, Polat MF, Yilmaz I, Akcay G. Serum paraoxonase levels in pancreatic cancer. Hepatogastroenterology 2003;50:ccxxv-vii.
7. Adkins S, Ganm KN, Mody M, La Du BN. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 1993;52:598-608.
8. Leviev I, Deakin S, James RW. Decreased stability of the M54 isoform of paraoxonase as a contributary factor to variations in human serum paraoxonase concentrations. J Lipid Res 2001;42:535-82.
9. van der Logt EMJ, Janssen CHJM, van Hooijdonk Z, et al. No association between genetic polymorphisms in NAD(P)H oxidase p22phox and Paraoxonase 1 and colorectal cancer risk. Anticancer Res 2006;25:1465-70.
10. Kerridge I, Lincz L, Scorgie F, Hickey D, Granter N, Spencer A. Association between xenobiotic gene polymorphisms and non-Hodgkin's lymphoma risk. Br J Haematol 2002;118:477-81.
11. Marchesani M, Hakkarainen A, Tuomainen T-P, et al. New paraoxonase 1 polymorphism I102V and the risk of prostate cancer in Finnish men. J Natl Cancer Inst 2003;95:812-8.
12. Antognelli C, Mearini L, Talesa VN, Giannantoni A, Mearini E. Association of CYP17, GSTP1, and PON1 polymorphisms with the risk of prostate cancer. Prostate 2005;63:240-51.
13. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
14. Ambrosone CB. Oxidants and antioxidants in breast cancer. Antioxid Redox Signal 2000;2:903-7.
15. Calle EE, Rodriguez C, Jacobs EJ, et al. The American Cancer Society cancer prevention study II nutrition cohort. Cancer 2002;94:2490-501.
16. Rothman KJ, Greenland S. Modern epidemiology. Baltimore: Lippincott, Williams and Wilkins; 1998.
17. Aviram M, Rosenblat M. Paraoxonases and cardiovascular diseases: pharmacological and nutritional influences. Curr Opin Lipidol 2005;16:393-9.
18. Li H-L, Liu D-P, Liang C-C. Paraoxonase gene polymorphisms, oxidative stress, and diseases. J Mol Med 2006;81:766-79.
19. Jacobs EJ, Thun MJ, Cornell, et al. Aspirin and other nonsteroidal anti-inflammatory drugs and breast cancer incidence in a large US cohort. Cancer Epidemiol Biomarkers Prev 2005;14:261-4.
20. Brophy VH, Jarvik GP, Richter RJ, Rozek LS, Schellenberg GD, Furlong CE. Analysis of paraoxonase (PON1) L55M status requires both genotype and phenotype. Pharmacogenetics 2000;10:453-60.
21. Blatter-Garin MC, Kalix B, De Free S, James RW. Aspirin use is associated with higher serum concentrations of the anti-oxidant enzyme, paraoxonase-1. Diabetologia 2003;46:593-4.
22. Jarvik GP, Hatsukami TS, Carlson C, et al. Paraoxonase activity, but not haplotype utilizing the linkage disequilibrium structure, predicts vascular disease. Arterioscler Thromb Vasc Biol 2003;23:1465-71.